CANNABINOIDS AND PAIN / DICIEMBRE 2016

 1: Minervini V, Dahal SS, France C. Behavioral Characterization of Kappa Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats. J Pharmacol Exp Ther.

 2: Guindon J. A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. Neuropharmacology. 

 3: Wilkerson JL, Ghosh S, Mustafa M, Abdullah RA, Niphakis MJ, Cabrera R, Maldonado RL, Cravatt BF, Lichtman AH. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and    attenuated heroin seeking behavior in mice. Neuropharmacology. 


 4: Tateo S. State of the evidence: Cannabinoids and cancer pain-A systematic review. J Am Assoc Nurse Pract. 


 5: Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J,
 Rosenbaum DM. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature.